GlassScriptPhysician profile
Mazen Beshara
NPI 1912993692
$4,759.29
in general payments reported to CMS, 2019-2025
30 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $231 · 2021: $29.01 · 2022: $227 · 2023: $1,141 · 2024: $1,063 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $839.25 | 2019-2025 | |
| Amgen INC. | $818.64 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.46 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $347.41 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Merck Sharp & Dohme LLC | $304.24 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $298.39 | 2019-2024 | Xarelto |
| Pfizer INC. | $280.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $225.15 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $198.28 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Sanofi-Aventis U.S. LLC | $159.07 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $117.54 | 2019-2023 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.76 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $98.22 | 2024-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $74.27 | 2023-2025 | Jot Dx, Cardiomems |
| Kiniksa Pharmaceuticals International, Plc | $68.24 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $49.23 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $46.54 | 2019-2020 | |
| Bridgebio Pharma, INC. | $45.82 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $42.84 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $36.45 | 2025 | |
| Scpharmaceuticals INC. | $34.43 | 2024-2025 | |
| Esperion Therapeutics, INC. | $31.30 | 2024 | Nexletol |
| Philips North America LLC | $29.71 | 2023 | |
| Novo Nordisk INC | $23.65 | 2024 | Wegovy |
| Medtronic, INC. | $18.54 | 2023 | Linq II |
| Kiniksa Pharmaceuticals, LTD. | $18.31 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $17.21 | 2025 | Onpattro |
| Astellas Pharma US INC | $14.04 | 2019 | |
| Vifor Pharma, INC. | $13.54 | 2019 | |
| Gilead Sciences, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Beshara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.